Potential first-to-market long acting levodopa combo from Impax/GSK shows promise in PD
This article was originally published in Scrip
Impax and GlaxoSmithKline have announced that IPX066 has demonstrated a statistically significant improvement over carbidopa-levodopa plus entacapone in reducing the percentage of “off-time” in the ASCEND-PD Phase III trial of Parkinson’s disease patients (Scripintelligence.com, 15 August, 2011). The strength of the extended release cabidopa-levodopa formulation lies in its increased "off time" compared to immediate-release formulations, reduced motor symptoms, and less frequent administration. However, the pricing strategy for IPX066 will have a critical bearing on the drug’s commercial success.